220 Shares in Insulet Co. (NASDAQ:PODD) Bought by Friedenthal Financial

Friedenthal Financial acquired a new position in shares of Insulet Co. (NASDAQ:PODD) in the fourth quarter, Holdings Channel.com reports. The firm acquired 220 shares of the medical instruments supplier’s stock, valued at approximately $57,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Private Advisor Group LLC raised its holdings in shares of Insulet by 92.6% during the second quarter. Private Advisor Group LLC now owns 3,187 shares of the medical instruments supplier’s stock valued at $643,000 after acquiring an additional 1,532 shares during the last quarter. BOKF NA grew its position in shares of Insulet by 10.3% in the second quarter. BOKF NA now owns 10,703 shares of the medical instruments supplier’s stock valued at $2,160,000 after purchasing an additional 1,001 shares in the last quarter. Thoroughbred Financial Services LLC acquired a new stake in shares of Insulet in the second quarter valued at approximately $407,000. Oppenheimer Asset Management Inc. lifted its position in Insulet by 16.6% during the second quarter. Oppenheimer Asset Management Inc. now owns 20,622 shares of the medical instruments supplier’s stock worth $4,162,000 after buying an additional 2,943 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its position in shares of Insulet by 4.9% during the 2nd quarter. Envestnet Asset Management Inc. now owns 87,718 shares of the medical instruments supplier’s stock valued at $17,702,000 after acquiring an additional 4,065 shares during the last quarter.

Insider Activity at Insulet

In other news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the sale, the chief accounting officer now owns 5,733 shares in the company, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.47% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

PODD has been the topic of several recent analyst reports. BTIG Research boosted their target price on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a report on Friday, November 8th. Morgan Stanley increased their price objective on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Barclays lifted their target price on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Citigroup raised their price objective on Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Finally, Canaccord Genuity Group boosted their price objective on shares of Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a report on Monday, December 9th. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $272.81.

Insulet Stock Down 1.4 %

Insulet stock traded down $3.84 during trading on Monday, reaching $267.99. The stock had a trading volume of 448,737 shares, compared to its average volume of 466,840. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $279.77. The business has a 50 day moving average price of $263.96 and a 200 day moving average price of $230.50. The stock has a market cap of $18.80 billion, a PE ratio of 45.89, a P/E/G ratio of 4.12 and a beta of 1.22. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.